ADM5 (adrenomedullin 5) is classified as a probable non-functional remnant of the adrenomedullin gene family [UniProt]. Despite putative annotations suggesting roles in G protein-coupled receptor signaling, hormone activity, and cardiovascular regulation, direct functional evidence for ADM5 is limited in the scientific literature. ADM5 shows altered expression in bladder cancer, appearing as an upregulated gene co-expressed with the long noncoding RNA NONHSAG034203 in low-grade non-muscle invasive bladder cancer 1. This co-expression pattern suggests potential involvement in bladder cancer biology, though the mechanistic contribution remains unclear. ADM5 was identified as a target of BMI-related DNA methylation variation in a twin study examining obesity and serum uric acid associations 2. The gene mapped within one of twenty differentially methylated regions identified through epigenome-wide association analysis, indicating that BMI-associated epigenetic changes may affect ADM5 regulation, though the functional consequence of this methylation is not established. Given its classification as a non-functional gene remnant, ADM5 likely represents a pseudogene without active protein product. Its appearance in disease-associated gene expression and methylation studies may reflect linked regulatory elements or epigenetic modifications affecting nearby functional genes rather than ADM5-specific pathology.